Figure 6.
Effects of CAB2-015 or BAK4-54 on oral sucrose self-administration. Pretreatment with CAB2-015, but not BAK4-54, dose-dependently inhibited oral sucrose self-administration behavior. N=12/group. *p<0.05, compared to the vehicle control group..